


RealRate

PHARMACEUTICAL 2018

Jazz Pharmaceuticals plc Rank 7 of 342









PHARMACEUTICAL 2018



RealRate

Jazz Pharmaceuticals plc Rank 7 of 342

The relative strengths and weaknesses of Jazz Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Jazz Pharmaceuticals plc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 86% points. The greatest weakness of Jazz Pharmaceuticals plc is the variable Other Net Income, reducing the Economic Capital Ratio by 4.0% points.

The company's Economic Capital Ratio, given in the ranking table, is 328%, being 282% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	968,277
Cost of Goods Sold	0
Intangible Assets	3,926,664
Liabilities, Current	293,947
Liabilities, Non-Current	0
Other Assets	58,651
Other Compr. Net Income	176,455
Other Expenses	214,513
Other Liabilities	0
Other Net Income	-88,734
Other Revenues	1,618,693
Property and Equipment	170,080
Research and Development	283,442
Selling, General and Administrative Expense	544,156

Output Variable	Value in 1000 USD
Assets	5,123,672
Liabilities	293,947
Expenses	1,042,111
Revenues	1,618,693
Stockholders Equity	4,829,725
Net Income	487,848
Comprehensive Net Income	576,076
Economic Capital Ratio	328%

